Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
98.64
-3.88 (-3.78%)
Streaming Delayed Price
Updated: 12:12 PM EST, Dec 8, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Incyte Corporation - Common Stock
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
24
25
Next >
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
↗
May 13, 2024
Via
Benzinga
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
May 13, 2024
From
Incyte Corporation
Via
Business Wire
The 3 Best Biotech Stocks to Buy in May 2024
↗
May 09, 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.
Via
InvestorPlace
NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals.
↗
May 08, 2024
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.
Via
Chartmill
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
↗
April 23, 2024
Via
Benzinga
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
↗
April 05, 2024
NASDAQ:INCY is showing good growth, while it is not too expensive.
Via
Chartmill
NASDAQ:INCY, a growth stock which is not overvalued.
↗
March 15, 2024
Despite its growth, NASDAQ:INCY remains within the realm of affordability.
Via
Chartmill
Incyte to Present at Upcoming Investor Conference
May 02, 2024
From
Incyte
Via
Business Wire
INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024
↗
April 30, 2024
INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
April 30, 2024
From
Incyte
Via
Business Wire
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
↗
April 26, 2024
In the world of growth stocks, NASDAQ:INCY shines as a value proposition.
Via
Chartmill
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
↗
April 23, 2024
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.
Via
Benzinga
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
↗
March 12, 2024
Via
Benzinga
NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases.
↗
March 04, 2024
INCYTE CORP (NASDAQ:INCY): good value for what you're paying.
Via
Chartmill
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
April 23, 2024
From
Incyte and Escient Pharmaceuticals
Via
Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
↗
April 17, 2024
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Incyte to Report First Quarter Financial Results
April 11, 2024
From
Incyte
Via
Business Wire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
↗
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
April 01, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 29, 2024
From
Incyte
Via
Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
↗
March 26, 2024
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.
Via
Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
↗
March 11, 2024
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.
Via
InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
March 10, 2024
From
Incyte Corporation
Via
Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
March 10, 2024
From
Incyte
Via
Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
↗
March 07, 2024
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Via
InvestorPlace
New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting
March 04, 2024
From
Incyte
Via
Business Wire
Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI
February 29, 2024
From
Incyte
Via
Business Wire
Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease
February 27, 2024
From
Incyte
Via
Business Wire
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
↗
February 26, 2024
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off.
Via
InvestorPlace
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
↗
February 22, 2024
For those who appreciate growth without the sticker shock, INCYTE CORP (NASDAQ:INCY) is worth considering.
Via
Chartmill
< Previous
1
2
...
8
9
10
11
12
13
14
15
16
...
24
25
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
